Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

CHANGE IN REGISTERED CAPITAL, PROPOSED ABOLISHMENT OF THE BOARD OF SUPERVISORS, AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND INTERNAL POLICIES

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") pursuant to Rule 13.51 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Reference is also made to the overseas regulatory announcement of the Company dated 26 August 2025.

(1) Change in registered capital

The board (the "**Board**") of directors of the Company (the "**Directors**") resolved on 26 August 2025 to approve an increase in the registered capital of the Company following the completion of the placing of new H shares under general mandate on 20 June 2025, pursuant to which an aggregate of 41,000,000 H shares were successfully allotted and issued by the Company to placees at a placing price of HK$25.35 per H share (the "**Placing**"). Upon completion of the Placing, the total issued share capital of the Company increased from 985,689,871 shares to 1,026,689,871 shares, including 766,394,171 A shares and 260,295,700 H shares, and the registered capital correspondingly increased from RMB985,689,871 to RMB1,026,689,871.

(2) Abolishment of the Board of Supervisors

In view of the updates of the Company Law of the People's Republic of China* (《中華人民共和國公司法》) (the "**PRC Company Law**"), the Guidelines for Articles of Association of Listed Companies* (《上市公司章程指引》) ("**Guidelines for Articles of Listed Companies**"), the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange* (《上海證券交易所科創板股票上市規則》) ("**STAR Market Listing Rules**"), and other laws, regulations and regulatory documents, and taking into account the circumstances of the Company, the Company proposes to abolish the board of supervisors (the "**Board of Supervisors**"), and the powers of the Board of Supervisors as stipulated in the PRC Company Law shall be exercised by the audit committee (the "**Audit Committee**") of the Board of Directors. Upon which, the rules of procedures of the Board of Supervisors (the "**Rules of Procedures of the Board of Supervisors**") shall be repealed accordingly, and the articles of association of the Company (the "**Articles of Association**" or "**Articles**"), the terms of reference of the Audit Committee, and other relevant policies shall be amended accordingly.

Until the proposal to abolish the Board of Supervisors is considered and approved at the general meeting of the Company, the Board of Supervisors shall continue to exercise its powers and functions in strict accordance with the requirements of laws, regulations and regulatory documents and safeguard the legitimate interests of the Company and all of its shareholders.

(3) Proposed amendments to the Articles of Association and the Rules of Procedures

Pursuant to the PRC Company Law, the Guidelines for Articles of Listed Companies, the STAR Market Listing Rules, the Guideline No. 1 for Self-regulation of Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation* (《上海證券交易所科創板上市公司自律監管指引第1號——規範運作》), and other laws, regulations and regulatory documents, and taking into account the circumstances of the Company, the Company proposes to amend (i) the Articles of Association; (ii) the rules of procedures of general meeting (the "**Rules of Procedures of General Meeting**"); (iii) the rules of procedures of the Board of Directors (the "**Rules of Procedures of the Board**", together with the Rules of Procedures of General Meeting, the "**Rules of Procedures**").

The proposed amendments to the Articles of Association and the Rules of Procedures, mainly include, among others, (i) the abolishment of the Board of Supervisors and the position of supervisor, with the Audit Committee exercising the powers and functions of the Board of Supervisors as stipulated in the PRC Company Law; and (ii) the enhancement or improvement of certain provisions of the Articles of Association and the Rules of Procedures in accordance with the requirements of the latest laws, regulations and regulatory documents, and taking into account the circumstances of the Company.

(4) Proposed amendments to and formulation of internal policies

The Company proposes to amend certain internal policies, including (i) the working rules of the independent non-executive Directors; (ii) the management policies for raised funds; (iii) the management policies for distribution of profits; (iv) the management policies for external investment; (v) the management policies for related party transactions; (vi) the management policies for external guarantees; (vii) the working rules of the general manager; (viii) the working rules of Board secretary; (ix) the investor relationship management policies; (x) the information disclosure management policies; (xi) the management policies for confidentiality; (xii) the management policies in relation to the prevention of controlling shareholders and related parties from appropriating funds of the Company; (xiii) the terms of reference of the Audit Committee; (xiv) the terms of reference of the remuneration and appraisal committee of the Board; (xv) the terms of reference of the nomination committee of the Board; (xvi) the terms of reference of the strategic committee of the Board; (xvii) the terms of reference of the compliance committee of the Board; (xviii) the internal audit management policies; and (xix) the information disclosure suspension and exemption business management policies.

The Company proposes to formulate new internal policies, including (i) the management policies for resignation of Directors and senior management; (ii) the management policies for the shares of the Company held by Directors and senior management and changes in shareholding; (iii) the polices for selection and appointment of accounting firms; and (iv) the information disclosure management policies for debenture bonds of the Company.

The proposed amendments to and formulation of the aforesaid internal policies have been reviewed and approved by the Board.

The change in registered capital and proposed abolishment of the Board of Supervisors, and the proposed amendments to the Articles of Association, the Rules of Procedures, the working rules of the independent non-executive Directors, the management policies for raised funds, the management policies for distribution of profits, the management policies for external investment, the management policies for related party transactions and the management policies for external guarantees shall be subject to the approval of the shareholders of the Company by way of ordinary resolution or special resolution at a general meeting to be convened by the Company. A circular containing, among other things, details of the aforesaid proposed amendments will be issued to the shareholders of the Company as soon as practicable.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 26 August 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Yang Yue, Mr. Li Zhongxian and Ms. Lu Kun as independent non-executive Directors.

* *For identification purposes only*